期刊
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE
卷 6, 期 5, 页码 829-841出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsptsci.3c00039
关键词
ionic liquid; navitoclax; apoptosis; skin fibrosis; topical; scleroderma
Pathological fibrosis characterized by persistent myofibroblast activation can be effectively treated by utilizing a newly developed ionic liquid formulation of NAVI for direct topical application to the skin. This treatment induces myofibroblast apoptosis and reverses established fibrosis, as demonstrated in a scleroderma mouse model. The COA-assisted topical delivery of NAVI increases therapeutic effect with minimal systemic circulation and toxicity.
Pathological fibrosis is distinguished from physiological wound healing by persistent myofibroblast activation, suggesting that therapies that induce myofibroblast apoptosis selectively could prevent progression and potentially reverse the established fibrosis, such as for scleroderma (a heterogeneous autoimmune disease characterized by multiorgan fibrosis). Navitoclax (NAVI) is a BCL-2/BCL-xL inhibitor with antifibrotic properties and has been investigated as a potential therapeutic for fibrosis. NAVI makes myofibroblasts particularly vulnerable to apoptosis. However, despite NAVI's significant potency, clinical translation of BCL-2 inhibitors, NAVI in this case, is hindered due to the risk of thrombocytopenia. Therefore, in this work, we utilized a newly developed ionic liquid formulation of NAVI for direct topical application to the skin, thereby avoiding systemic circulation and off-targetmediated side effects. The ionic liquid composed of choline and octanoic acid (COA) at a 1:2 molar ionic ratio increases skin diffusion and transportation of NAVI and maintains their retention within the dermis for a prolonged duration. Topical administration of NAVI-mediated BCL-xL and BCL-2 inhibition results in the transition of myofibroblast to fibroblast and ameliorates pre-existing fibrosis, as demonstrated in a scleroderma mouse model. We have observed a significant reduction of alpha-SMA and collagen, which are known as fibrosis marker proteins, as a result of the inhibition of antiapoptotic proteins BCL-2/BCL-xL. Overall, our findings show that COA-assisted topical delivery of NAVI upregulates apoptosis specific to myofibroblasts, with minimal presence of the drug in the systemic circulation, resulting in an accelerated therapeutic effect with no discernible drug-associated toxicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据